Dyne Therapeutics, Inc. (DYN)
| Market Cap | 391.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -126.15M |
| Shares Out | 51.53M |
| EPS (ttm) | -2.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,588,336 |
| Open | 7.83 |
| Previous Close | 8.05 |
| Day's Range | 7.20 - 8.31 |
| 52-Week Range | 6.99 - 22.92 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 34.75 (+357.2%) |
| Earnings Date | n/a |
About DYN
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for DYN stock is "Buy." The 12-month stock price forecast is 34.75, which is an increase of 357.24% from the latest price.
News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
New York, New York--(Newsfile Corp. - January 25, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors...
Why Shares of Dyne Therapeutics Dropped 18.1% on Tuesday
A clinical hold regarding one of the company's therapies brought Dyne's shares to a 52-week low.
FDA Issues Clinical Hold On Dyne's IND For Duchenne Muscular Dystrophy Program
The FDA has placed a clinical hold on Dyne Therapeutics Inc's (NASDAQ: DYN) investigational New Drug (IND) application to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrop...
Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy
WALTHAM, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with ge...
Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with ge...
Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate
Dyne Therapeutics (DYN) files an investigational new drug application in the United States for a clinical study on its investigational candidate DYNE-251 to address Duchenne Muscular Dystrophy.
Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscula...
- DYNE-251, Dyne's First DMD Program, is Being Developed for Patients with Mutations Amenable to Skipping Exon 51 -
Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
- Robust In Vivo Data Presented at Scientific Meetings Support Advancement of Dyne's Co-lead Candidates into the Clinic -
Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&...
- Investigational New Drug (IND) Submissions Anticipated for DYNE-251 in DMD During the Fourth Quarter of 2021 and for DYNE-101 in DM1 During the First Quarter of 2022 -
Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy Program
Dyne Therapeutics Inc (NASDAQ: DYN) has announced new data presented today during the 2021 Muscle Study Group Annual Scientific Meeting for its Duchenne muscular dystrophy (DMD) program. DMD is a rare d...
Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Ann...
- Dystrophin Restoration of 90% of Wild-Type Levels Observed in the Diaphragm and 78% in the Heart with ~80% Dystrophin-Positive Fibers After a Single Dose in mdx Mouse Model -
Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021
- “The Muscle to Move to the Clinic” Event Will Highlight Preclinical Data Supporting Advancement of Dyne's DM1 and DMD Programs Toward Clinical Trials and Anticipated Timelines, and Feature Leading Exp...
Dyne Therapeutics to Present at Chardan's Virtual 5th Annual Genetic Medicines Conference
WALTHAM, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with g...
Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robu...
- New In Vivo Data Also Show Sustained Knockdown of Toxic Human Nuclear DMPK RNA and Foci Reduction -
Dyne Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
- On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - New In Vivo Data from DM1 and DMD Programs to be Presented at Scientific Me...
Dyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD S...
- FORCE™ platform enables targeted muscle delivery with lead FSHD program candidate demonstrating potent suppression of DUX4 biomarkers in patient cell line -
Dyne Therapeutics Announces Chief Scientific Officer Transition
- Co-founder Romesh Subramanian, Ph.D., stepping down as chief scientific officer and will serve as an advisor after leading successful R&D and pipeline-building efforts -
Dyne Therapeutics' Myotonic Dystrophy Gene Therapy Shows Encouraging Action In Animal Studies
Dyne Therapeutics Inc (NASDAQ: DYN) has announced new preclinical data from its myotonic dystrophy type 1 (DM1) program, including results demonstrating sustained knockdown of toxic human nuclear DMPK R...
Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of...
- Robust Reduction in DMPK RNA in Multiple Muscles at Four Weeks in Novel In Vivo Model Developed by Dyne; Additional In Vitro Data Support Advancement of Lead DM1 Candidate -
Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
- On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 -
New Preclinical Data from Dyne Therapeutics' Myotonic Dystrophy Type 1 Program to be Featured in Presentations During...
Company to host webcast including leading DM1 expert, Dr. Charles Thornton, following presentations on May 14, 2021 Company to host webcast including leading DM1 expert, Dr. Charles Thornton, following ...
Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
- Preclinical Data Further Validate FORCE™ Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Between Q4'21 and Q4'22 -
Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer
Seasoned Clinical Leader Brings Deep Experience in Drug Development, Including Approval of an Oligonucleotide Therapy in Neuromuscular Disease
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease
Dyne Therapeutics Announces Pricing of $168 Million Public Offering
WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with ge...